Michelle A Allan, RN MNurs(NP)
,
Monash Neurology, Monash Health, Melbourne, Australia
Lisa B Grech, PhD, MPsych
,
Melbourne School of Psychological Sciences, University of Melbourne, Parkville, VIC, Australia
Adriana Cartwright, BA
,
Department of Clinical Neuroscience, St Vincent's Hospital, Melbourne, Australia
Joshua J Mardan, BPsychSc(Hons), Assoc MAPS
,
Department of Medicine, Monash health, School of Clinical Sciences, Monash Univeristy, Melbourne, Australia
Janet Harding, N/A
,
Department of Medicine, Monash health, School of Clinical Sciences, Monash University., Monash Univeristy, Melbourne, Australia
Tim O'Maley, M.N.Sc (NP) B.H.Sc; Grad Cert Management; NNC
,
Department of Neurology, Princess Alexandra Hospital, Brisbane, Australia
Sharryn Savickas, RN
,
Department of Neurosciences, Barwon Health, Geelong, Australia
Meena Sharma, RN MNurs(NP)
,
Neurology Outpatient Department, Liverpool Hospital, Sydney, Australia
Paul Stockle, BNurse
,
Centre for Neuroscience Innovation, Adelaide, Australia
Bronwyn Coulton, RN MNurs(NP)
,
Department of Neurosciences, Eastern Health, Melbourne, Australia
Belinda Bardsley, RN BN MSCN Dip Management
,
MS Nurses Australasia Incorporated, Melbourne, Australia
Ernest Butler, MD, PhD
,
Department of Neurology, Monash Health, Clayton, VIC, Australia
Background: Medication adherence is crucial to maximise disease modifying therapy (DMT) outcomes. Understanding the relationship between treatment burden and adherence across different oral DMT administration schedules, side effects and monitoring requirements is important for clinical decision-making, maximising DMT adherence in multiple sclerosis (MS).
Objectives: The current study aims to understand the relationship between treatment burden and medication adherence for oral self-administered DMTs in people with MS, as well treatment burden and medication adherence differences between oral DMTs.
Methods: This multi-site prospective longitudinal trial will recruit 323 participants with MS, newly prescribed oral DMTs: cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, within routine care (n=84 currently recruited). We will measure treatment burden, quality of life, depression and anxiety using: a customized survey; Treatment Satisfaction Questionnaire for Medication; MS Quality of Life-54; and Hospital Anxiety and Depression Scale, at baseline, 3- and 12-months. Adherence will be assessed using pharmaceutical prescription data across 24-months enrolment.
Results: We will present preliminary baseline results of DMT differences in treatment burden and quality of life across oral DMTs.
Conclusions: Information gained will assist prescribing decision-making with consideration for implications of treatment burden on medication adherence, minimising unnecessary healthcare costs and maximizing quality of life for people with MS.
